439608-30-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Methylthio-5-methylbenzoxazole is utilized as an intermediate in the synthesis of pharmaceutical drugs. Its unique structure and properties make it a valuable component in the development of new medications.
Used in Agrochemical Industry:
2-Methylthio-5-methylbenzoxazole also serves as an intermediate in the production of agrochemicals, where it contributes to the formulation of effective pesticides and other agricultural products.
Used as Antimicrobial Agent:
2-Methylthio-5-methylbenzoxazole is recognized for its antimicrobial properties, making it a potential candidate for use in applications requiring the inhibition of microbial growth, such as in medical or industrial settings.
Used as Antioxidant:
2-Methylthio-5-methylbenzoxazole's antioxidant properties suggest its potential use in various applications where protection against oxidative damage is necessary, such as in the food industry or in cosmetic products to prevent spoilage and extend shelf life.

InChI:InChI=1/C9H9NOS/c1-6-3-4-8-7(5-6)10-9(11-8)12-2/h3-5H,1-2H3

Upstream product

• 22876-22-8 4-methyl-1,3-benzoaxazolidine-2-thione 
• 100-66-3 methoxybenzene 
• 77-78-1 dimethyl sulfate 
• 119-33-5 4-methyl-2-nitrophenol 
• 95-84-1 3-amino-4-hydroxytoluene 
• 22876-22-8 5-methylbenzo[d]oxazole-2-thiol 
• 74-88-4 methyl iodide 

Relevant academic research and scientific papers

HMOX1 inducers

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

Preparation method for methylthio-substituted benzo[d]oxazole derivative

The invention discloses a preparation method for a methylthio-substituted benzo[d]oxazole derivative, i.e., 5-methyl-2-(methylthio)benzo[d]oxazole. According to the invention, 2-nitro-4-methylphenol is used as a starting raw material and undergoes reduction, ring closure and methylation so as to obtain the methylthio-substituted benzo[d]oxazole derivative. The prepared derivative is an important medical intermediate.

Regioselective thiolation of arenes and heteroarenes: C-H functionalization strategy for C-S bond formation

A facile transition-metal-free oxidative cross-dehydrogenative coupling reaction involving selective formation of a C-S bond leading to the synthesis of arylthiobenzoxazoles, heteroarylthiobenzoxazoles, and arylthiobenzothiazoles has been described. This highly regioselective C-H functionalization reaction with electron-rich aromatic systems including heteroaromatics is achieved by reversing the reactivity of sulfur in the presence of a suitable oxidant and strong acid. (Chemical Equation Presented).

Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane (CP-810,123), a novel α7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: Synthesis, SAR development, and in vivo efficacy in cognition models

A novel α7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4- diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that α7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia. 2009 American Chemical Society.

5-PYRIDINONE SUBSTITUTED INDAZOLES

5-pyridinone substituted indazoles of the formula and methods of their use are presented.

Pharmaceutical compositions for CNS and other disorders

The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant α7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant α7 nicotinic receptor agonist.